Clinical development for GLP-1 receptor agonists (GLP-1 RAs) involves operational requirements that can extend beyond standard drug trial execution. Type 2 diabetes and obesity studies may involve large patient populations, extended treatment periods, repeated metabolic assessments, and endpoints covering glycemic control, body weight, cardiovascular risk, and other disease-related outcomes.
For sponsors selecting a GLP-1 RA CRO, the key question is therefore not simply whether a provider can recruit patients or manage clinical sites. Evaluation should also consider its understanding of the target patient population, investigator networks, endpoint requirements, data management processes, and regulatory expectations.
Why do GLP-1 RA trials require specialized clinical operations?
GLP-1 RA trials require indication-specific planning because diabetes and obesity programmes can have different patient populations and clinical objectives.
Type 2 diabetes studies may focus on glycemic control, while obesity programmes may emphasize sustained weight reduction and related health outcomes. Some programmes may also investigate cardiovascular, renal, or liver-related effects. FDA guidance addresses efficacy endpoints for antidiabetic drug development and provides separate considerations for drugs intended for weight reduction.
These differences influence site selection, eligibility criteria, visit schedules, endpoint collection, retention strategies, and statistical planning.
How should patient recruitment be approached?
Patient recruitment should focus on access to a protocol-matched population rather than simply the size of a site’s database.
Diabetes patients can vary in disease duration, background medication, glycemic control, cardiovascular risk, and comorbidities. Eligibility requirements involving HbA1c, treatment history, renal function, or cardiovascular characteristics can further reduce the available population.
A practical feasibility assessment can examine patient demographics, referral pathways, competing studies, investigator experience, and historical recruitment performance. Screening failures should also be considered when forecasting enrollment.
Obesity studies may require participants to meet specific body-mass-index and health criteria. Longer treatment periods can also make participant retention an important operational consideration.
What should sponsors look for in an endocrinology site network?
A suitable site network should combine access to relevant patients with investigators and staff capable of following the protocol consistently.
Endocrinology practices can provide access to patients receiving ongoing metabolic care, but specialty alone is not enough. Sites also need appropriate research infrastructure, trained staff, laboratory capabilities, and sufficient capacity for repeated study visits.
ICH E6(R3) emphasizes evaluating whether investigators and trial sites have suitable qualifications, resources, facilities, and staff. For GLP-1 RA programmes, feasibility teams may therefore assess previous metabolic trial experience, recruitment sources, competing studies, laboratory capabilities, and patient visit capacity.
Tigermed reports more than 200 collaborating sites with GLP-1 RA trial experience. Its stated therapeutic coverage includes diabetes, obesity, cardiovascular disease, non-alcoholic fatty liver disease, and chronic kidney disease.
Which endpoints require particular operational attention?
Metabolic endpoints require consistent collection procedures because many measurements are repeated throughout a study.
Depending on the protocol, these may include HbA1c, fasting glucose, body weight, waist circumference, blood pressure, lipid measurements, and renal markers. FDA guidance addresses efficacy endpoints for antidiabetic trials, while FDA’s 2025 draft guidance on obesity and overweight drug development discusses sustained weight reduction and other relevant outcomes.
Operational standardization is therefore important. Protocols should define measurement conditions, equipment requirements, laboratory procedures, and data collection methods. Additional cardiovascular or renal outcomes may require clinical event reporting, laboratory data, medication information, and source-data verification.
A CRO with relevant therapeutic experience can translate these requirements into site training, visit procedures, data review, and query management.
How should cardiovascular outcomes be managed?
Cardiovascular and broader cardiometabolic outcomes should be incorporated according to clearly defined study objectives and endpoint strategies.
Depending on the programme, investigators may collect cardiovascular events, blood pressure, lipid parameters, renal function, or other measures alongside primary efficacy endpoints. Each outcome should have predefined definitions and collection procedures.
FDA guidance on multiple endpoints highlights the importance of careful planning when studies evaluate several outcomes. For event-based cardiovascular endpoints, adjudication procedures may also be considered depending on the study design.
Clear processes established before trial execution can help ensure that sites collect and document relevant clinical evidence consistently.
What should sponsors consider when choosing a GLP-1 RA CRO?
Regulatory planning should be considered from the beginning of clinical development rather than only during submission preparation.
The intended indication, target population, efficacy measures, safety considerations, and regional regulatory requirements can influence study design and data collection. For multinational programmes, coordination between clinical operations, statistics, medical writing, regulatory, and safety teams may also be required.
Tigermed states that its GLP-1 RA solution covers activities from preclinical development through Phase IV, including clinical development strategy, medical writing, medical monitoring, clinical operations, biostatistics, clinical pharmacology, quantitative pharmacology, regulatory submission, drug safety surveillance, and central laboratory capabilities. For sponsors considering a glp-1 ra programme, these capabilities may be relevant when clinical evidence needs to support regulatory objectives across different development stages.
How can sponsors evaluate operational experience?
Sponsors should assess a CRO according to the specific population, endpoints, operational model, and regulatory pathway of the planned programme.
Useful questions include whether the CRO can access suitable diabetes and obesity investigators, how recruitment feasibility is established, how cardiometabolic endpoints are collected, and whether it has experience with regulatory requirements in the target markets.
Tigermed describes its GLP-1 team as including professionals with experience in GLP-1 biology, pharmacology, and clinical research. Sponsors can further evaluate these capabilities by requesting relevant study examples, recruitment performance, site-level experience, endpoint procedures, quality metrics, and regulatory submission experience.
Operational requirements may also vary when sponsors consider decentralized clinical trials, making it important to assess whether the selected model fits the protocol and patient population.
Overall, GLP-1 RA CRO selection should be based on how well a provider’s capabilities match the clinical question, target population, endpoints, and regulatory strategy of the programme.
